Looking at 2021’s US Food and Drug Administration (FDA) drug approvals, one might not have known there was still a major health crisis underway. More than 50 new drugs were waved through — close to 2018’s all-time high and on a par with those in 2020 (Fig. 1 and Table 1), the first pandemic year. On top of its usual workload, the FDA faced political pressure to accelerate already speedy approval timelines for COVID-19 vaccines and therapeutics…

Fonte: Nature Biotechnology | VOL 40 | February 2022 | 155–162 | www.nature.com/naturebiotechnology 155

Para acessar a publicação na íntegra clique aqui